Key Takeaway: The article discusses the AUA 2025 conference focusing on translational correlates using urinary minimal residual disease (MRD). It highlights the significance of this research area but lacks detailed information on findings or implications. The announcement is part of a broader agenda for the conference.
Price reaction · baseline $17.94 (2025-04-04T13:33:00.000Z) · hit during market hours · 1 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-4.1%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
Press Releases
Video Library
Careers
AUA 2025 TRANSLATIONAL CORRELATES USING URINARY MRD